Hepatitis C Therapy
Infergen combination therapy more effective than Rebetron
Published in Hepatitis Weekly, December 9th, 2002
InterMune, Inc., (ITMN) announced that positive preliminary results of an investigator initiated, prospective randomized phase IV clinical trial comparing the use of Infergen (interferon alfacon-1) plus ribavirin versus interferon alfa-2b plus ribavirin (Rebetron) for the treatment of chronic hepatitis C infections were presented at the 53rd annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.
Patients treated with Infergen in combination with ribavirin achieved a higher sustained virologic response (SVR), the study's primary endpoint, compared with those patients treated with Rebetron.
"These data suggest...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2002-12-09)
More Articles from Hepatitis Weekly
- Chronic Hepatitis C
Enzyme not indicative of sustained response after interferon - Hepatectomy
Postsurgical hepatitis linked to shortened survival - Cryoglobulinemia
Gene rearrangements frequent in hepatitis C patients - Drug Resistance
Gene transfer sensitizes liver cancer cells to chemotherapy - Hepatitis C Risk Factors
Virus thrives in sweat glands of chronic hepatitis C patients - Liver Cancer Therapy
Copper chelator trientine mediates liver cancer killing - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
